Correlation of Age, PSA Value, Gleason Score, and Staging with Metastasis in Prostate Cancer

Puti Rania Esfandiary, Ferry Safriadi, Akhmad Mustafa

Abstract


Prostate cancer is the fifth most common cancer among men in Indonesia and carries a substantial risk of metastasis. However, data on prognostic factors such as age, prostate-specific antigen (PSA) value, Gleason score, and local stage among Indonesian patients are still limited. This retrospective cross-sectional study analyzed medical records of prostate cancer patients treated at Dr. Hasan Sadikin General Hospital, Bandung, between 2019–2022. Independent variables were age, PSA value, Gleason score, and local stage; the dependent variable was metastatic status. Data were analyzed using chi-square and multivariate logistic regression tests. A total of 81 patients were included, of whom 44 (54.3%) had metastases. Bivariate analysis showed significant associations of PSA value, Gleason score, and local stage with metastasis (p<0.05). In multivariate analysis, only Gleason score and local stage remained significant independent predictors (p<0.05). The findings indicate that Gleason score and local tumor stage are reliable predictors of metastasis in prostate cancer, while age and PSA are not independent predictors in this cohort. Gleason score and local stage should be prioritized for risk assessment in prostate cancer management in Indonesian hospitals.


Keywords


Neoplasm metastasis, prostatic neoplasms, risk factors

Full Text:

PDF

References


  1. Paz JC. Oncology. In: Acute Care Handbook for Physical Therapists [Internet]. Elsevier; 2014 [cited 2023 June 30]. p. 265–81. Available from: http://dx.doi.org/10.1016/B978-1-4557-2896-1.00011-1
  2. Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer. JAMA. 2018;319(18):1901–13. doi:10.1001/jama.2018.3710.
  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. doi:10.3322/caac.21660
  4. Safriadi F, Novesar AR. Five-year profiles of prostate cancer patients in a tertiary hospital in indonesia. Majalah Kedokteran Bandung. 2021;53(2):101–6. doi:10.15395/mkb.v53n2.2212
  5. Manna F La, Karkampouna S, Zoni E, De Menna M, Hensel J, Thalmann GN, et al. Metastases in prostate cancer. Cold Spring Harb Perspect Med. 2019;9(3):1–15. doi:10.1101/cshperspect.a033688
  6. Leslie SW, Soon-Sutton TL, Skelton WP. Prostate Cancer. [Updated 2024 Oct 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470550/
  7. Peng C, Juan C, Mao W, Jinghe Y, Renli T. Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients. Eur Rev Med Pharmacol Sci. 2022;26(11):3832–9. doi:10.26355/eurrev_202206_28950
  8. Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer. 2015;122(1):78–83. doi:10.1002/cncr.29691
  9. Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, et al. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. PLoS One. 2020;15(1):e0228447. doi:10.1371/journal.pone.0228447
  10. Cosma G, Acampora G, Brown D, Rees RC, Khan M, Pockley AG. Prediction of pathological stage in patients with prostate cancer: a neuro-fuzzy model. PLoS One. 2016;11(6):e0155856. doi:10.1371/journal.pone.0155856
  11. Young SM, Bansal P, Vella ET, Finelli A, Levitt C, Loblaw A. Systematic review of clinical features of suspected prostate cancer in primary care. Can Fam Physician. 2015;61(1):e26–35.
  12. NIH News in Health. Understanding Health Risks : Improve Your Chances for Good Health [Internet]. newsinhealth.nih.gov. 2017 [cited 2023 June 30]. Available from: https://newsinhealth.nih.gov/2016/10/understanding-health-risks#:~:text=Knowing%20the%20risks%20you%20and,your%20doctor%20make%20informed%20decisions
  13. Jin K, Qiu S, Jin H, Zheng X, Zhou X, Jin D, et al. Survival outcomes for metastatic prostate cancer patients treated with radical prostatectomy or radiation therapy: a seer-based study. Clin Genitourin Cancer. 2020;18(6):e705–e722. doi:10.1016/j.clgc.2020.05.005
  14. Liu D, Kuai Y, Zhu R, Zhou C, Tao Y, Han W, et al. Prognosis of prostate cancer and bone metastasis pattern of patients: a SEER-based study and a local hospital based study from China. Sci Rep. 2020;10(1):9104. doi:10.1038/s41598-020-64073-6
  15. Clark R, Vesprini D, Narod SA. The effect of age on prostate cancer survival. Cancers (Basel). 2022;14(17):4149. doi:10.3390/cancers14174149
  16. Kim H, Lee S, Byun SS, Hong SK. Clinical outcomes and prognosis of metastatic prostate cancer patients ≤60-year-old. World J Urol. 2021;39(12):4319–25. doi:10.1007/s00345-021-03785-4.
  17. Shih HJ, Fang SC, An L, Shao YJ. Early-onset prostate cancer is associated with increased risks of disease progression and cancer-specific mortality. Prostate. 2021;81(2):118–126. doi:10.1002/pros.24087
  18. David MK, Leslie SW. Prostate-Specific Antigen. In: StatPearls. Treasure Island (FL): StatPearls Publishing; September 10, 2024 [cited 2025 May 9]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557495/.
  19. Montironi R, Santoni M, Mazzucchelli R, et al. Prostate cancer: from Gleason scoring to prognostic grade grouping. Expert Rev Anticancer Ther. 2016;16(4):433–40. doi:10.1586/14737140.2016.1160780
  20. Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO Guideline PART I. J Urol. 2021;205(1):14–21. doi:10.1097/JU.0000000000001375




DOI: https://doi.org/10.15395/mkb.v58.4225

Article Metrics

Abstract view : 9 times
PDF - 4 times

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


 


Creative Commons License
MKB is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats